Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,12 USD | +3,70% | +1,82% | -9,68% |
09/05 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Akebia Therapeutics, Inc. rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024 | CI |
Omzet 2024 * | 173 mln. 159 mln. | Omzet 2025 * | 159 mln. 147 mln. | Marktkapitalisatie | 235 mln. 216 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -64 mln. -58,97 mln. | Nettowinst (verlies) 2025 * | -73 mln. -67,27 mln. | EV/omzet 2024 * | 1,36 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,47 x |
K/w-verhouding 2024 * |
-4,31
x | K/w-verhouding 2025 * |
-3,43
x | Werknemers | 167 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,79% |
Recentste transcriptie over Akebia Therapeutics, Inc.
1 dag | +3,70% | ||
1 week | +1,82% | ||
1 maand | -13,85% | ||
3 maanden | -34,50% | ||
6 maanden | +4,67% | ||
Lopend jaar | -9,68% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 01-07-13 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 01-04-22 |
Michel Dahan
COO | Chief Operating Officer | 45 | 01-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 12-12-18 |
Adrian Adams
CHM | Chairman | 73 | 12-12-18 |
LeAnne Zumwalt
BRD | Director/Board Member | 65 | 16-02-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.01% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
31-05-24 | 1,12 | +3,70% | 2 114 042 |
30-05-24 | 1,08 | +4,85% | 2 226 275 |
29-05-24 | 1,03 | -3,74% | 3 395 784 |
28-05-24 | 1,07 | -2,73% | 2 845 383 |
uitgestelde koers Nasdaq, 31 mei 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-9,68% | 235 mln. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. | |
+77,64% | 8,87 mld. |